Kornimate/medical-research-clean huggingface dataset:
ambrisentan for the improvement in right ventricular strain in scleroderma associated pulmonary arterial hypertension

Conditions: Pre-Pulmonary Atrial Hypertension

Summary: this research study is looking at the use of the drug ambrisentan and if it can improve right ventricle function in people with systemic sclerosis-associated pre-pulmonary arterial hypertension. it is also looking at using right ventricle function changes as a marker of disease severity.

this research study is looking at the use of the drug ambrisentan and if it can improve right ventricle function in people with systemic sclerosis-associated pre-pulmonary arterial hypertension. it is also looking at using right ventricle function changes as a marker of disease severity. pre-pulmonary arterial hypertension is a borderline elevation in blood pressure in the lungs. pre-pulmonary arterial hypertension is not currently treated with the drug therapies that are used for pulmonary arterial hypertension. it represents a group of patients that are at risk for developing pulmonary arterial hypertension. the administration of ambrisentan is the experimental part of this study. ambrisentan has not been approved by the fda for use of improving right ventricle function in people with pre-pulmonary arterial hypertension. you will still receive your normal clinical care. the purpose of this study is to learn more about ambrisentan and its role in treating systemic sclerosis-associated pre-pulmonary arterial hypertension. ambrisentan is already approved for use in people with systemic sclerosis-associated pulmonary arterial hypertension, but this study wants to research its role in people with pre-pulmonary arterial hypertension.

Eligibility criteria:
inclusion criteria: * age \>18 years, \< 80 years * systemic sclerosis with any of the following features: 1. duration of raynaud's phenomena \>8 years 2. anticentromere antibody positivity 3. isolated nucleolar-pattern ana positivity 4. extensive telangiectasias 5. dlco \< 60% in the absence of extensive ild 6. fvc%/dlco% \>1.6 7. unexplained dyspnea * right heart catheterization-proven pre pah (mean pap 20-25 mmhg and pulmonary capillary wedge pressure \<15 mmhg) * systolic blood pressure \>100 mmhg * reliable contraception for women of childbearing age * informed consent exclusion criteria: * \ 80 years * left ventricular ejection fraction \< 55% * systolic or diastolic left ventricular congestive heart failure * liver disease (abnormal ast/alt, chronic hepatitis, or cirrhosis) * extensive ild or fvc\< 60% * pregnant * breast-feeding women * cyclosporine use

Keywords: pre-pulmonary atrial hypertension
telephone administered psychotherapy for the treatment of depression for veterans in rural areas

Conditions: Depressive Disorder; Depression

Summary: the purpose of this study is to examine the efficacy of telephone-administered cognitive-behavioral therapy (t-cbt) in treating major depression among veterans served by community-based outpatient clinics (cbocs) in the veteran's integrated service network (visn) 21, which serves rural areas in northern california and (visn) 12, which serves rural areas surrounding the hines, il va hospital.

more than 20% of patients in primary care have depressive disorders. while primary care is the principal venue for treatment for depression, fewer than 25% of depressed patients receive adequate treatment for their depression. these outcomes can be worse when there are barriers to treatment such as living in a rural area. several studies have found that given a choice, about two-thirds of depressed primary care patients prefer psychotherapy or counseling over antidepressant medication. this is a controlled, randomized trial in which subjects meeting criteria for major depressive disorder (mdd) from primary care settings in visn 21 including cbocs will be randomly assigned to one of two conditions: 1) a 16-session manualized telephone administered cognitive behavioral therapy (t-cbt) delivered over 20 weeks or 2) a treatment-as-usual (tau) condition. telephone-administered cognitive behavioral therapy (t-cbt) is an intervention aimed at improving coping skills and social functioning. it is divided into two phases: 1) an initial treatment phase consisting of 12 weekly sessions aimed at reducing symptoms of depression, and 2) a booster phase in which 4 sessions are provided at increasingly greater intervals to target maintenance of treatment gains. t-cbt, administered by doctoral level psychologists, will be compared to a treatment-as-usual (tau) condition that controls for the natural course of depression during the course of treatment.

Eligibility criteria:
inclusion criteria: * has a dsm-iv diagnosis of major depressive disorder as assessed using the mini * has a telephone * able to speak and read english * at least 18 years of age * able to give informed consent * must be registered at a va community-based, outpatient clinic (cboc) at va eureka or va ukiah or va santa rosa, or va manteno, or va elgin, or va la salle exclusion criteria: * has a hearing, voice or visual impairment that would prevent participation in t-cbt * meets criteria for dementia * is diagnosed with psychotic disorder, bipolar disorder, substance abuse with clinical consensus, or current severe ptsd. * is currently receiving psychotherapy or planning to receive psychotherapy during the 20-week treatment phase of the study * has a history of suicide attempts or is at high risk for suicide.

Keywords: cognitive-behavioral therapy telephone psychotherapy clinical trial primary care clinic treatment for depression
combined effects of visceral manipulation and noble technique on post-partum females with diastasis recti

Conditions: Diastasis Recti

Summary: diastasis recti is characterized by an abnormal expansion of the gap between the medial sides of the rectus abdominis muscle and a lengthening of the linea alba (increased inter-recti distance). it is mainly caused by excessive intra-abdominal pressure. the abdominal muscles and connective structures expand from the growing uterus during pregnancy. low back pain is a prevalent complaint that can result from various factors, including weakened core muscles and functional disability. the aim of the study would assess of combined effect of visceral manipulation and noble technique on inter-rectal distance, low back pain and functional disability in post-partum females with diastasis recti.

a randomized controlled trial will be conducted in dhq hospital toba tek singh. a nonprobability convenience sampling technique will be used. there will be 34 participants. participants will meet with inclusion criteria and be divided into two groups a and b. in group a 17 participants will receive visceral manipulation technique with noble technique for 30 minutes per session, three sessions per week for 6 weeks. while in group b 17 participants will just receive noble technique exercises for 15 min per session, three sessions per week for 6 weeks. participants will be assessed before and after treatment through; digital nylon calipers for diastasis recti, nprs for pain, and quebec back pain disability scale (qbpds) to assess lbp-related functional. data will be analyzed during spss software version 21

Eligibility criteria:
inclusion criteria: * age between 22 to 35. * primiparous women with vaginal delivery and an ird of \>2 cm. * three to six months postpartum with the presence of diastasis rectus abdominis. * patients having moderate low back pain in nprs. exclusion criteria: * acute malignancy * recent abdominal or pelvic surgery * having undergone spinal surgery in the previous six months * serious spinal pathology * serious cardiovascular or metabolic disease pregnancy * herniation pain

Keywords: diastasis recti low back pain post partum females visceral manipulation
computational cardiac imaging analysis to guide ventricular tachycardia ablation procedures (ai-vt)

Conditions: Ventricular Tachycardia (VT); Premature Ventricular Contraction (PVC); Ventricular Fibrillation

Summary: the purpose of this study is to evaluate the clinical outcomes (clinical efficacy and safety) of using supplemental non-invasive computational ecg and cardiac imaging analysis tools to help guide ablation of ventricular tachycardia.


Eligibility criteria:
inclusion criteria: 1. age between 21 and 100 2. evidence of ventricular tachycardia on ecg, telemetry or by cied interrogation. exclusion criteria:

Keywords: electrocardiography, arrhythmia mapping, 3d mapping, electroanatomic mapping, cardiac computed tomography, artificial intelligence, computational modeling
prevention of covid-19 complications in high-risk subjects infected by sars-cov-2 and eligible for treatment under a cohort atu ('autorisation temporaire d'utilisation') or or authorisation for early access (aap). a prospectvie cohort.

Conditions: SARS-CoV Infection; Covid19

Summary: this is a prospective, multicentric, non comparative study aiming to evaluate the clinical and virological evolution of high-risk patients infected with sars-cov-2 treated withtin the framework of a cohort atu ('autorisation temporaire d'utilisation') or authorisation for early access (aap) delivered by the french drug agency (ansm).


Eligibility criteria:
inclusion criteria: * adults with the criteria for covid-19 treatment within the french compassionate program (atu/aap) * adults covered by the french social health coverage * adults who signed the informed consent form exclusion criteria: * exclusion criteria described in the french compassionate program (atu/aap) * patient participating in another biomedical research with an exclusion period ongoing at inclusion * vulnerable patient (adults legally protected: under judicial protection, guardianship, or supervision, persons deprived of their liberty) * pregnant or breastfeeding woman
long-term effect of θ burst magnetic stimulation on clinical symptoms of alzheimer disease

Conditions: Repetitive Transcranial Magnetic Stimulation

Summary: this was a randomized, single-blind, parallel, placebo-controlled clinical trial assessing the efficacy of neuronavigational tbs among patients with ad. fourty late-onset ad were included in the study, all the patients were divided into tbs groups and drug treatment group. drug intervention group ad patients with drug regimen (donepezil 5mg / d) and primary care guidance, once every three months follow-up. tbs group is treated with tbs (a course of treatment every 3 months); after completing 4 treatments/follow-ups a year, evaluate the changes in moca, other clinical symptoms and multi-domain cognition tests, and brain changes in structure and function.


Eligibility criteria:
inclusion criteria: * subject diagnosed with early alzheimer's disease or related diseases according to nincds-acdrada criteria. * subjects must have a mmse score between 10 and 27,indicating mild cognitive impairment or dementia * cdr score ≤ 2 * subject under treatment by iache for at least 3 weeks. * psychotropic treatments are tolerated if they were administered and unchanged for at least 3 months exclusion criteria: * cdr \> 2 * any history or clinical signs of other severe psychiatric illnesses (like major depression,psychosis or obsessive compulsive disorder). - page 5 of 6 \[draft\] - * history of head injury,stroke,or other neurologic disease. * organic brain defects on t1 or t2 images. * history of seizures or unexplained loss of consciousness. * implanted pacemaker,medication pump,vagal stimulator,deep brain stimulator. * family history of medication refractory epilepsy. * history of substance abuse within the last 6 months.
evaluation of the safety of the medical device simeox®

Conditions: Broncho-degenerative Disease; Chronic Obstructive Airway Disease; Cystic Fibrosis; Idiopathic Bronchiectasis; Ciliary Dyskinesia; Chronic Bronchitis

Summary: the purpose of this study is to determine whether the medical device "simeox" is safe in the treatment of respiratory diseases, in comparison with traditional physiotherapy.


Eligibility criteria:
inclusion criteria: * patient over 18, male or female. * patient affected by broncho-degenerative disease, chronic obstructive airway disease, cystic fibrosis, idiopathic bronchiectasis, ciliary dyskinesia and/or chronic bronchitis. * hospitalization for a minimum of five days or a maximum of 8 days. * bronchial clearance is usually productive. * fvc and / or fev \<85% predicted, with stable lung function. * agreement to participate to the study and signature of the informed consent form * social security coverage. exclusion criteria: * patient infected with bacteria resistant to antibiotics. * bronchial clearance is not usually productive. * patient with contra-indication for physiotherapy bronchial clearance. * patient who received a lung transplant. * care requires more than 2 sessions of chest physiotherapy daily. * duration of mechanical ventilation \> 8h/day. * patient with an episode of hemoptysis during the month before inclusion. * patient with an episode of pneumothorax during the last month. * pregnant or lactating women. * patient with a disability and/or unwillingness to follow protocol requirements. * patient participating in another clinical study or having tested an experimental drug within 30 days prior to his inclusion in the study. * patient ( s) with another condition which, according to the investigator , may interfere with the result or conduct of the trial and thus justify their non- inclusion in the study.
pulsed electromagnetic therapy versus whole body vibration on quadriceps strength post burn

Conditions: Pulsed Electromagnetic Field; Whole Body Vibration; Burns

Summary: the purpose of the study is to evaluate which is more effective pulsed electromagnetic field therapy or whole-body vibration on quadriceps strength after chronic burn

severe burn is associated with excessive muscle wasting and atrophy. muscle wasting is defined as unintentional weight loss of 5%- 10% of muscle mass, and severely burned patients are reported to lose up to 25% of total body mass acutely. (dirks et al., 2016). these are worsened by deconditioning (eg, prolonged bed rest, immobilization, and inactivity). (baker et al., 2007). furthermore, the need of this study is developed from the lack in the quantitative knowledge and information in the published studies about the effect of pulsed electromagnetic field therapy and whole-body vibration on quadriceps strength after chronic burn. this study will be designed to provide a guideline about the effect of pulsed electromagnetic field therapy and whole-body vibration on quadriceps strength after chronic burn

Eligibility criteria:
inclusion criteria: 1. both sex. 2. their ages will be ranged from 25 to 40 years. 3. have second degree burn of 10 % to 25 %. 4. their body mass index (bmi) will not exceed 34.9 kg/m2. 5. all patients will be clinically and medically stable when attending the study. exclusion criteria: 1. unstable cardiovascular problems like arrhythmia and heart failure. 2. diabetes mellitus. 3. chronic chest disease. 4. patients on medications affecting muscle power as steroids. 5. auditory and visual problems. 6. pregnancy \& lactation. 7. patients with history of epilepsy. 8. clinically significant peripheral vascular disease. 9. musculoskeletal or neurological limitation to physical exercise. 10. any cognitive impairment that interferes with prescribed exercise procedures. 11. amputation of lower limb.
femoral/sciatic block for knee surgery

Conditions: Knee Injuries

Summary: knee arthroplasty has a high potential for postoperative pain. this study compares analgesia and postoperative bleeding from intrathecal morphine with the continuous femoral and a single-shot sciatic nerve blockades.

this study aims to compare intrathecal morphine as a technique for analgesia with the femoral nerve blockade associated with a single-shot sciatic nerve blockade. analgesic efficacy, the incidence of adverse effects, and postoperative bleeding were evaluated

Eligibility criteria:
inclusion criteria: * patients aged over 18 years old, american society of anesthesiologists (asa) physical status from i to iii who underwent total knee arthroplasty exclusion criteria: * patients aged below 18 years old, asa iv or v physical status, infection near the puncture site, coagulation disorders, preexisting neurological disorders, allergy report to local anesthetics, pregnancy and lactation, contraindications to spinal block and refusal to sign an informed consent form

Keywords: analgesia nerve block pain, postoperative
a study to determine preferences towards interface products

Conditions: Sleep Disorder; Breathing-Related

Summary: enrolled naïve participants will be randomized to one of two arms, the investigational or control arm. once randomized the institutions will fit the participant with the procedures outlined in the protocol. each participant will be required to trial the mask for a period of 90 days. any unscheduled visits or calls that occur during the participants 90 days documented.


Eligibility criteria:
inclusion criteria: * adult volunteers (ages 21-85) * willing and able to provide informed consent * able to follow instructions * able to read and speak in english as their primary language * currently diagnosed with sleep apnea through an in-lab sleep (polysomnography (psg)) or home sleep testing, but has not started therapy and/or been fit with a mask. exclusion criteria: * pre-existing conditions such as bullous lung disease, pathologically low blood pressure, bypassed upper airway, pneumothorax, pneumocephalus, cerebral spinal fluid (csf) leaks, cribriform plate abnormalities, and prior history of head trauma that has resulted in current cognitive dysfunction. * prescribed an adaptive servo ventilation (asv) device * the presence of physical or mental limitations that would limit the ability to test the mask. * obstructive sleep apnea (osa) diagnosis achieved through a split night sleep study * known allergy to silicone * unique facial features (i.e. deformities of the face and/or head, piercings, etc) that could interfere with the use of masks. * employee of philips or spouse of a philips employee * currently participating in another interventional research study or planned participation in another interventional research study during the trial period (by self-report) * surgery involving the eyes, ears, nose, sinuses, or upper airway within the last 90 days. * planned surgical procedures involving the head, neck, face (eyes, ears, nose), or lung during the trial period. * uncontrolled or poorly managed gastroesophageal reflux * impaired cough reflex * untreated or symptomatic hiatal hernia * untreated glaucoma * untreated chronic dry eyes * unable to remove the sleep apnea mask without the assistance of others * use of prescription drugs that induce vomiting

Keywords: sleep apnea
etodalac, etoricoxib and dexamethasone for prevention of pain ,swelling and trismus following third molar surgery

Conditions: Trismus; Edema; Pain

Summary: the purpose of this study is to determine whether etodalac, etoricoxib and dexamethasone are effective for prevention of pain ,swelling and trismus following third molar surgery


Eligibility criteria:
inclusion criteria: * patients who are refered for third molar extraction to our center * must be able to swallow tablets exclusion criteria: * diabetes mellitus * thyroid diseases * cardiovascular diseases * renal diseases * hepatic diseases * respiratory system diseases * adrenal diseases * allergy to etodalac, etoricoxib or dexamethasone * gastric ulcers * psychiatric diseases * pregnant or breast feeding womans

Keywords: trismus edema pain
efficacy and safety of the dts-g2 system in patients with axillary hyperhidrosis

Conditions: Primary Focal Hyperhidrosis, Axilla

Summary: this is a prospective, multi-center, parallel, randomized, blinded study. the study has two groups, where in one study group the subjects receive treatment for axillary hyperhidrosis (excessive underarm sweating) with the dts-g2 system in both axilla ("treatment group"). the other study group receives a sham treatment in both axilla where the subjects will have the same procedure performed but no energy from the device will be applied ("sham group"). subjects will be randomized in a 2:1 ratio (treatment group: sham group). subjects enrolled in the study will be blinded regarding which study group they are in. the study hypothesis is that subjects that receive the treatment will have a reduction in underarm sweating compared to those in the sham group, as measured by a quality of life questionnaire. all subjects will undergo follow up assessments at 14 days, 30 days, 3 months and 6 months post final treatment session. subjects randomized to the treatment group will also have follow-up visits at 9 months and 12 months post final treatment session.


Eligibility criteria:
inclusion criteria: * baseline gravimetric measurement of spontaneous resting sweat production of at least 50 mg/5 min at room temperature in each axilla * poor quality-of-life rating on the hyperhidrosis disease severity scale * primary focal axillary hyperhidrosis evidenced by at least two of the standard criteria * female subjects of child-bearing potential must not be pregnant or lactating and must agree to not become pregnant during the course of the study including follow-up period * female subjects over 40 must have had a mammogram in the last 2 years * subjects must be willing to comply with study visits and requirements exclusion criteria: * subject has secondary hyperhidrosis (e.g., endocrinopathy, medications) * subject has active infection * subject is pregnant or lactating * subject has had prior surgery for axillary hyperhidrosis * subject has had axillary injections of botulinum toxin a in the last year * subject has used prescription antiperspirants in the last 14 days or plans to use them during the study period * subject has used oral anticholinergics in the last 4 weeks * subject is a prisoner or under incarceration * subject is participating in a another clinical trial (or has in the last 30 days) * subject has history of cancer (some exceptions) * subject has a pacemaker or other electronic implant * subject requires supplemental oxygen

Keywords: axillary hyperhidrosis primary focal